Igniting the
power of
promising science
to unleash new possibilities for patients
Latest News
SpringWorks Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
Read MoreSpringWorks Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Read MoreSpringWorks Therapeutics Receives FDA Fast Track Designation for Nirogacestat for the Treatment of Adult Patients with Desmoid Tumors
Read More
It starts with patients. The inspiration for the science.
At SpringWorks Therapeutics, we see the groundbreaking potential in that science. We see what it could mean for people without options, without treatments, and without hope. Unfortunately, we also see that sometimes, that science is overlooked, de-prioritized and unfulfilled, unable to make its full impact.
Every day, we work to turn that promising science into useful medicine. We identify and advance stagnating drugs, test new combination therapies, and are always searching for new compounds to develop.
Our Focus
We pioneer efficient pathways for drug development for patients with severe rare diseases and cancer.
Desmoid Tumors
Desmoid tumors are rare and debilitating soft-tissue tumors that can occur in both children and adults, and that can cause severe morbidities such as pain, internal bleeding, disfigurement and limited range of motion. SpringWorks is developing a gamma secretase inhibitor for the treatment of desmoid tumors.
Neurofibromatosis Type 1
NF1 is a rare genetic disorder caused by mutations in the NF1 gene that affects both children and adults. Throughout their lifetime, a large proportion of patients will develop NF1-associated plexiform neurofibromas (PNs), which are tumors that grow on nerves throughout the body, causing severe pain, disfigurement, and loss of range of motion. SpringWorks is developing a MEK 1/2 inhibitor for NF1 patients with PNs.
Desmoid Tumors
Desmoid tumors are rare and debilitating soft-tissue tumors that can occur in both children and adults, and that can cause severe morbidities such as pain, internal bleeding, disfigurement and limited range of motion. SpringWorks is developing a gamma secretase inhibitor for the treatment of desmoid tumors.
Neurofibromatosis Type 1
NF1 is a rare genetic disorder caused by mutations in the NF1 gene that affects both children and adults. Throughout their lifetime, a large proportion of patients will develop NF1-associated plexiform neurofibromas (PNs), which are tumors that grow on nerves throughout the body, causing severe pain, disfigurement, and loss of range of motion. SpringWorks is developing a MEK 1/2 inhibitor for NF1 patients with PNs.
Our Values
Care Hard
We take caring very seriously. We care about our patients deeply, intensely, and relentlessly. Every day, we care for patients by working harder to develop solutions others haven’t.
Ambition Without Ego
We exist to ignite the power of promising science to unleash new possibilities for patients. To make this audacious ambition a reality, we must not let personal pride, empty rhetoric or ego get in the way.
Think Deeply, Act Quickly
Our team is measured, comprehensive, and thoughtful about every move we make, but we’re also driven by a sense of urgency because we know that patients are waiting. We delicately and expertly balance thinking and acting while always upholding our commitment to the highest standards of ethics and integrity.
Good Enough is Never Enough
“Good enough” is never enough for the patients and families counting on us. That’s why we constantly push ourselves to become smarter, better, and faster in pursuit of our ambition.
In It Together
We’re a team, first and foremost. Each and every SpringWorker is all in with their coworkers, partners and patients. We do our best work when we all get together, hurling jokes and big ideas and collectively making it happen.
Our Partners
Building strong partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the full potential of science for patients.
Our Team
SpringWorks offers the best of both worlds — we’re a start-up with a head start. We operate with the agility and flexibility of a start-up, but are rapidly growing as we prepare to start late-stage studies with our two lead development programs.
